A Framework to Predict the Molecular Classification and Prognosis of Breast Cancer Patients and Characterize the Landscape of Immune Cell Infiltration. (7th June 2022)

• Record Type: Journal Article
• Authors: Zheng, Kun; Luo, Zhiyong; Zhou, Yilu; Zhang, Lili; Wang, Yali; Chen, Xiuqiong; Yao, Shuo; Xiong, Huihua; Yuan, Xianglin; Zou, Yanmei; Wang, Yihua; Xiong, Hua
• Other Names: Tsui Po-Hsiang Academic Editor.
• Is Part Of: Computational and mathematical methods in medicine. Volume 2022(2022)
• Publication Date: 2022-06-07
• Subjects: Medicine -- Computer simulation -- Periodicals; Medicine -- Mathematical models -- Periodicals; 610.11
• DOI: 10.1155/2022/4635806
• Languages: English
• ISSNs: 1748-670X

Abstract

Abstract : It is known that all current cancer therapies can only benefit a limited proportion of patients; thus, molecular classification and prognosis evaluation are critical for correctly classifying breast cancer patients and selecting the best treatment strategy. These processes usually involve the disclosure of molecular information like mutation, expression, and immune microenvironment of a breast cancer patient, which are not been fully studied until now. Therefore, there is an urgent clinical need to identify potential markers to enhance molecular classification, precision prognosis, and therapy stratification for breast cancer patients. In this study, we explored the gene expression profiles of 1, 721 breast cancer patients through CIBERSORT and ESTIMATE algorithms; then, we obtained a comprehensive intratumoral immune landscape. The immune cell infiltration (ICI) patterns of breast cancer were classified into 3 separate subtypes according to the infiltration levels of 22 immune cells. The differentially expressed genes between these subtypes were further identified, and ICI scores were calculated to assess the immune landscape of BRCA patients. Importantly, we demonstrated that ICI scores correlate with patients' survival, tumor mutation burden, neoantigens, and sensitivity to specific drugs. Based on these ICI scores, we were able to predict the prognosis of patients and their response to immunotherapy. Together, these findings provide a realistic scenario to stratify breast cancer patients for precision medicine.